Research led by Roy Herbst suggests that #NC318 , both alone and in combination with pembrolizumab, improved response rates and clinical outcomes for some patients with #NSCLC .
Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp OncoAlert
yalecancercenter.org/news-article/n…

“Opinion: The cancer drug shortage is a disgrace” -- read a just-published CNN op-ed from our Board Chair & Past President Eric Winer, MD on the current oncology #drugshortages : fal.cn/3AtEQ

Yale Cancer Center is filled with pride that Pat LoRusso is a nominee for AACR president, with ballot opening today. We are all 100% behind her, and I know she will be an extraordinary leader for AACR. Yale Cancer Center Smilow Cancer Hospital

Fantastic to be back in Chicago ASCO annual meeting. It feels like old times apart from all the masks -- making the name tags more important than ever before. Program clearly demonstrates that we have continued to make advances these past 2+ years. #ASCO22

I am profoundly sad to learn of the passing of Angelo Di Leo. He was so thoughtful, gentle, and creative. Saw Angelo 6/2019 and struck by his bravery and straightforward approach to his illness. He will be missed by entire cancer community. Am thinking of his wife + daughter.

Congrats to Dr. Lori Pierce on a brave, bold, and truly spectacular opening session. Presidential address truly moving. We are all wiser as a result. #asco21 Lynn M. Schuchter, MD, FASCO @ASCO

Thank you all for the congratulations and well wishes. I am thrilled and honored to be the ASCO president-elect-elect. This is a tough winter, but we all just have to get through it and the future is bright. Thanks again!

Looks like neratinib/capecitabine is a reasonable option for 3rd line therapy and beyond for patients with metastatic HER2+ breast cancer. It would be interesting to know how neratinib/capecitabine would compare with trastuzumab/capecitabine. #ASCO19

Final Kristine results are enormously encouraging. Almost certainly, a combination of molecular markers and clinical response can identify a relatively large group of patients who will ultimately be able to receive T-DM1 +P alone and avoid standard cytoxic chemotherapy. Bravo.

It is clear that women with ER+ breast cancer are at substantial risk of late recurrence in years 5-15. It is equally clear that extended hormonal therapy with currently available agents is only a small part of the solution. We need new approaches for this critical problem.

ABC4 meeting in Lisbon —Dr. Bella Kaufman gave insightful, profound, and revealing talk on being oncologist and living w/metastatic BC —WOW

The DCIS controversy is news but not new. Need to identify women who will do fine w/o treatment. Prospective clinical trials needed now.